Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours

Csáki, C.; Ferencz, T.; Schüler, D.; Borsi, Joseph D.

doi:10.1016/s0959-8049(97)10065-x

Cited by 28 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Csa´ki et al randomized 15 children who were undergoing chemotherapy for different solid tumors to either treatment with RhEPO or no treatment. Two trends were seen: in the RhEPO-treated group the weight loss was more limited and the performance status better preserved [29].…”

Section: Discussionmentioning

confidence: 98%

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Halteren¹,

Bongaerts²,

Verhagen³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Halteren¹,

Bongaerts²,

Verhagen³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Twenty-seven and 30% of the patients received RT in the study and control groups, respectively. All patients were followed for 15.16 ± 4.98 (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) weeks. The durations of follow-up for epoetin and control groups were similar (16.04 ± 4.78 [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] and 14.70 ± 4.53 [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] weeks, res...…”

Section: Resultsmentioning

confidence: 99%

“…Although there are numerous valuable studies assessing the effectiveness of epoetin alfa in children with cancer, there are not as many studies with epoetin beta (Table 3) [10,[12][13][14][15][16][17][18][19]25]. Only two studies have been carried out with epoetin beta in children with thalassemia and in renal transplant recipients [26,27].…”

Section: Discussionmentioning

confidence: 99%

“…Minimum, maximum, and mean Hb concentrations and the time of the maximum and minimum Hb concentrations in the treatment period were determined. A hemoglobin concentration less than 7 g/dL was taken as the indication for RBC transfusion [10,13,15,17,19]. No patient was given iron supplementation, which might alter Hb levels.…”

Section: Methodsmentioning

confidence: 99%

“…The response rate in adults, as measured by elevation of hemoglobin and diminution of RBC transfusion requirements, ranges from 21 to 85% [6][7][8]. To date, some important studies have examined the role of rHuEPO in children with cancer by utilizing epoetin alfa [10][11][12][13][14][15][16][17][18][19]. In our prospective and historical controlled study, epoetin beta was used to find out the effect of rHuEPO on hemoglobin (Hb) concentrations and RBC transfusion requirement in children receiving CT ± radiotherapy (RT).…”

mentioning

confidence: 99%

See 2 more Smart Citations

RECOMBINANT HUMAN ERYTHROPOIETIN BETA THERAPY: An Effective Strategy to Reduce Transfusion Requirement in Children Receiving Anticancer Treatment

Çorapçıoğlu

Aksu

Başar

et al. 2008

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

In recent years erythropoietic agents have become important tools in the management of anemia in cancer patients, improving hemoglobin (Hb) concentrations, reducing the need for transfusion, and enhancing quality of life. In this prospective and historically controlled study, the effects of epoetin beta on Hb concentrations and red blood cell transfusion needs in children with cancer receiving chemotherapy or radiotherapy have been investigated. Epoetin beta (150 U/kg/day, 3 days a week) was given subcutaneously to 22 children with cancer when Hb concentration < or = 10 g/dL. Data from these patients were compared with those from 20 historical control patients. Hb concentrations were studied weekly in the first 9 weeks, then weekly or fortnightly thereafter. Minimum, maximum, and mean Hb concentrations, frequency of red blood cell transfusion, and the number of red cell packs given were noted. Hb concentrations in weeks 6, 8, and 11 were clearly higher in the study group than the controls. The minimum Hb concentration of the study group was significantly higher than than the control group (7.98 +/- 0.73 [6.70-9.68] g/dL and 7.24 +/- 1.40 [5.50-11.20] g/dL, respectively [p = .038]). A total of 8 units of erythrocyte suspension was given to 4 of the 22 patients in the epoetin group (0.36 unit per patient), while 16 of the 20 patients in the control group received 37 units of erythrocyte suspension in total (1.85 units per patient). The red cell transfusion requirement and the units of transfused erythrocytes per patient were clearly lower in the epoetin group (p < .001 for both of the parameters). No drug-related side effects were noted during epoetin therapy. Epoetin beta therapy provides significant increase in Hb concentrations in children with cancer under anticancer treatment, especially after the sixth week of therapy. Administration of epoetin beta prevents profound decreases in Hb concentrations in the course of therapy and effectively reduces the need for red blood cell transfusions. Epoetin beta was found to be safe and effective in the dosage and the scheme it was used in our study.

show abstract

The Changing Transfusion Practice of Neonatal and Pediatric Surgery

Kling¹,

Jabbour²,

Kumar³

2005

Transfusion‐Free Medicine and Surgery

View full text Add to dashboard Cite

Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours

Cited by 28 publications

References 11 publications

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

RECOMBINANT HUMAN ERYTHROPOIETIN BETA THERAPY: An Effective Strategy to Reduce Transfusion Requirement in Children Receiving Anticancer Treatment

The Changing Transfusion Practice of Neonatal and Pediatric Surgery

Contact Info

Product

Resources

About